Table 1.
Patient characteristics.
| Characteristic value | Number |
|---|---|
| At primary diagnosis | |
| Age | |
| Median | 62 |
| Range | 52–80 |
| Serum PSA (ng/mL) | |
| Median | 13 |
| Range | 1–181 |
| Gleason score | |
| Median | 8 |
| Range | 6–10 |
| Treatment modality, n (%) | |
| Primary IMRT | 11 (45.8) |
| Primary prostatectomy | 5 (20.8) |
| Hormone and chemotherapy | 4 (16.7) |
| Seed brachytherapy | 2 (8.3) |
| Cryotherapy | 1 (4.2) |
| SBRT | 1 (4.2) |
| Time initial diagnosis to SBRT (mo) | |
| Median | 51 |
| Range | 2–229 |
| ADT initial treatment, n (%) | 23 (95.8) |
| At SBRT | |
| PSA (ng/mL) | |
| Median | 9 |
| Range | 0–1806 |
| Age (years) | |
| Median | 69 |
| Range | 53–88 |
| Location of lesions, n (%) | |
| Bone | 15 (62.5) |
| Lymph node | 7 (29.2) |
| CNS | 1 (4.2) |
| Lung | 1 (4.2) |
| Number of metastasis, n (%) | |
| ≤4 | 9 (37.5) |
| >4 | 15 (62.5) |
| CTV (cm3) | |
| Median | 21.9 |
| Range | 0.6–626.8 |
| Previous radiation to SBRT site, n (%) | 10 (41.7) |
| Systemic treatment, n (%) | |
| None or not ADT refractory | 4 (16.7) |
| ADT refractory | 5 (20.8) |
| ADT + docetaxel received | 15 (62.5) |
| After SBRT | |
| PSA (ng/mL) | |
| Median | 6 |
| Range | 0–554 |
| Recurrence, n (%) | |
| None | 11 (45.8) |
| Local (in SBRT field) | 1 (4.2) |
| Distant (out of SBRT field) | 12 (50.0) |